

In Vitro and in Vivo Protein Oxidation Induced by Alzheimer's Disease Amyloid -Peptide (1-42)

D. ALLAN BUTTERFIELD,^{a,c} SERVET M. YATIN,^a AND CHRISTOPHER D. LINK^b

^aDepartment of Chemistry, Center of Membrane Sciences, and Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky 40506, USA

^bInstitute for Behavioral Genetics, University of Colorado, Boulder, Colorado 80309, USA

Amyloid β -peptide (A β) is thought by many researchers to be central to the pathogenesis of Alzheimer's disease (AD) (reviewed in Ref. 1). In addition, oxidative stress, manifested by protein oxidation and lipid peroxidation, is apparent in AD brain.^{2,3} Our laboratory developed a comprehensive hypothesis for neurotoxicity in AD brain that unites these two observations and provides a testable framework for much of the AD literature. We proposed an $\text{A}\beta$ -associated free radical oxidative stress model for neuronal death in AD brain (Fig. 1). In AD brain, the predominant forms of A β are A β (1-40) and A β (1-42). Consistent with our model and in ways completely inhibited by free radical scavengers (antioxidants), A β leads to lipid peroxidation^{4,5} and protein oxidation⁶⁻⁸ in various brain membrane systems; generates reactive oxygen species (ROS);




FIGURE 1. Flow diagram of our comprehensive model for A β -associated free radical oxidative stress-induced neurotoxicity in Alzheimer's disease brain. See Ref. 2 for a review and greater details.

not.¹⁰ If our model is correct, then one may predict that transgenic animals overexpressing A (1-42) should show increased protein oxidation *in vivo*. *Caenorhabditis elegans* transgenic animals expressing full-length A (1-42) were produced,¹¹ and protein oxidation was determined. In agreement with predictions of our model and with our earlier studies in AD brain,¹⁰ A (1-42)-expressing animals had significantly increased protein oxidation *in vivo* (FIG. 2C). To gain some insight into potential molecular mechanisms by which A (1-42) led to protein oxidation *in vivo*, methionine was mutated to cys in this *in vivo* model of A (1-42) expression. Consistent with previous *in vitro* studies of methionine substitution in A (25-35) and A (1-40) (2,13), no *in vivo* protein oxidation was found.

These findings are consistent with the A β -associated free radical oxidative stress model of neurotoxicity in AD brain² (FIG. 1). Other sequelae of A (1-42)-induced *in vitro* and *in vivo* oxidative stress and their inhibition by antioxidants are currently



FIGURE 2. A. Reactive oxygen species production in cultured hippocampal neurons to which A β (1-42) had been added. ROS are assessed by fluorescence of 2,7-dichlorofluorescein, formed by reaction of peroxy radicals or hydrogen peroxide to the DCF dye employed. B. Protein carbonyls (dark bars) a measure of protein oxidation, and cell survival (lighter bars) of hippocampal neurons to which A β (1-42) had been added. Percent increased protein carbonyls in A β (1-42)-treated neurons over that of controls; mean \pm SEM: 163 \pm 2%, p 0.01, n = 3. Percent cell survival was decreased significantly in A β (1-42)-treated neurons (76.3% of control cells, p = 0.01, n = 3). C. In vivo protein oxidation was found in *C. elegans* 4Ci6. Per9i.0212 0exp0 01.56J/F10 11full-lengt(In vivo)JTJ/F10 1 2r/F7 1 Tf e

under investigation. These current and ongoing studies may provide additional insight into AD pathogenesis and therapeutic strategies.

ACKNOWLEDGMENTS

This work was supported in part by NIH grants AG-051191 and AG-10836.

REFERENCES

1. SELKOE, D. 1994. Alzheimer's disease: a central role of amyloid. *J. Neuropathol. Exp. Neurol.* **53**: 438–447.
2. BUTTERFIELD, D.A. 1997. β -amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. *Chem. Res. Toxicol.* **10**: 495–506.
3. MARKESBERY, W.R. 1997. Oxidative stress hypothesis in Alzheimer disease. *Free Radical Biol. Med.* **23**:134–147.
4. BUTTERFIELD, D.A., K. HENSLEY, M. HARRIS, M. MATTSON & J. M. CARNEY. 1994. β -Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. *Biochem. Biophys. Res. Commun.* **200**: 710–715.
5. KOPPAL, T., R. SUBRAMANIAM, J. DRAKE, M.R. PRASAD & D.A. BUTTERFIELD. 1998. Vitamin E protects against Alzheimer's amyloid peptide (25-35)-induced changes in neocortical synaptosomal membrane lipid structure and composition. *Brain Res.* **786**: 270–273.
6. SUBRAMANIAM, R., T. KOPPAL, M. GREEN, S. YATIN, B. JORDAN, J. DRAKE & D.A. BUTTERFIELD. 1998. The free radical antioxidant vitamin E protects cortical synaptosomal membranes from amyloid beta-peptide (25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer's disease. *Neurochem. Res.* **23**: 1403–1410.
7. YATIN, S.M., M. AKSENOV & D.A. BUTTERFIELD. 1999. The antioxidant vitamin E modulates amyloid β -peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. *Neurochem. Res.* **24**: 427–435.
8. HARRIS, M., K. HENSLEY, D.A. BUTTERFIELD, R.A. LEEDLE & J.M. CARNEY. 1995. Direct evidence of oxidative injury produced by the Alzheimer's amyloid beta-peptide (1-40) in cultured hippocampal neurons. *Exp. Neurol.* **131**: 193–202.
9. BUTTERFIELD, D.A. & E.R. STADTMAN. 1997. Protein oxidation processes in aging brain. *Adv. Cell Aging Gerontol.* **2**: 161–191.
10. HENSLEY, K., N. HALL, R. SUBRAMANIAM, P. COLE, M. HARRIS, M. AKSENOV, M. AKSENOVA, S.P. GABBITA, J.F. WU, J.M. CARNEY, M. LOVELL, W.R. MARKESBERY & D.A. BUTTERFIELD. 1995. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation, *J. Neurochem.* **65**: 2146–2156.
11. FAY, D., A. FLUET, C. JOHNSON & C. LINK. 1998. In vivo aggregation of beta-amyloid peptide variants. *J. Neurochem.* **71**: 1616–1625.
12. VARADARAJAN, S., S. YATIN, J. KANSKI, F. JAHANSHAKI & D.A. BUTTERFIELD. 1999. Methionine residue 35 is important in amyloid β -peptide-associated free radical oxidative stress. Submitted for publication.